Montauk Renewables, Inc. filed a Form 8-K on November 16, 2026, disclosing that Chief Financial Officer Kevin Van Asdalan notified the company on November 15, 2026, of his intention to resign effective December 9, 2026.
Surgery Partners, Inc. filed a Form 8-K on November 16, 2026, disclosing that its indirect wholly owned subsidiary, Surgery Center Holdings, Inc., commenced a consent solicitation from holders of $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032.
Strive, Inc. filed a Form 8-K on November 16, 2026, disclosing a bitcoin purchase of 251 coins during the period from November 7, 2026 through November 13, 2026, along with updated holdings and capital structure data as of November 13, 2026.
Strategy Inc filed a Form 8-K on November 16, 2026, disclosing its at-the-market offering activity, bitcoin purchases, share repurchase program updates, and cash dividend declarations for the period ending November 15, 2026.
Relmada Therapeutics, Inc. filed a current report on November 16, 2026, announcing the appointment of Jørn Skibsted Jakobsen, MD, PhD, as its Chief Development Officer.
Optimum Communications, Inc. filed a Form 8-K on November 16, 2026, disclosing that its wholly owned subsidiary CSC Holdings LLC elected not to make approximately $102.5 million in interest payments due that same day, entering a 30-day grace period under the applicable indentures.
Walmart Inc. filed a Form 8-K on November 16, 2026, disclosing the appointment of Joseph E. Creed to its Board of Directors, effective November 13, 2026, along with his committee assignments and prorated director compensation details.
Digimarc Corporation filed an 8-K on November 16, 2026, disclosing a Cooperation Agreement dated November 15, 2026, with Ocho Investments LLC, under which the Board was expanded and three new directors were appointed while four existing directors submitted resignations effective December 31, 2026.
Pasithea Therapeutics Corp. filed a current report on Form 8-K on November 16, 2026, disclosing that on November 13, 2026, the company announced initial clinical data from its ongoing Phase 1/1b study of PAS-004 and received FDA clearance of an Investigational New Drug application …
Super League Enterprise, Inc. filed a current report on November 16, 2026, disclosing that on November 13, 2026, the company purchased eight Bitcoin as part of its exploration of Bitcoin as a treasury asset.